OC64 StethAid: mobile technology for smart auscultation in children

Abstract

screen (from those with history of in-utero exposure) were significant predictors for onset of NAS requiring pharmacological intervention at >96 HOL (OR 0.21; p value 0.011). Conclusions The majority of infants who required pharmacological treatment for NAS during their postnatal observation period were diagnosed within the first 120 HOL. Those atrisk infants, born to mothers with a known history of exposure, who have a negative urine toxicology screen for both baby and mother, should be monitored beyond 5 days as they tend to have a later presentation.